$12.04
3.53% today
Nasdaq, Apr 01, 07:17 pm CET
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Mesoblast Limited Sponsored ADR Stock price

$12.48
-4.67 27.23% 1M
+4.31 52.75% 6M
-7.32 36.97% YTD
+6.40 105.26% 1Y
+4.04 47.87% 3Y
+3.72 42.47% 5Y
-15.00 54.59% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
+0.37 3.06%
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Key metrics

Market capitalization $1.58b
Enterprise Value $1.67b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 295.36
P/S ratio (TTM) P/S ratio 279.80
P/B ratio (TTM) P/B ratio 3.12
Revenue (TTM) Revenue $5.66m
EBIT (operating result TTM) EBIT $-51.63m
Free Cash Flow (TTM) Free Cash Flow $-49.73m
EPS (TTM) EPS $-0.93
P/E forward negative
P/S forward 78.77
EV/Sales forward 83.15
Short interest 1.58%
Show more

Is Mesoblast Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Mesoblast Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy
100%

Financial data from Mesoblast Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
5.66 5.66
27% 27%
100%
- Direct Costs -3.73 -3.73
113% 113%
-66%
9.38 9.38
150% 150%
166%
- Selling and Administrative Expenses 23 23
8% 8%
414%
- Research and Development Expense 33 33
22% 22%
588%
-47 -47
-
-836%
- Depreciation and Amortization 4.30 4.30
-
76%
EBIT (Operating Income) EBIT -52 -52
29% 29%
-912%
Net Profit -103 -103
26% 26%
-1,822%

In millions USD.

Don't miss a Thing! We will send you all news about Mesoblast Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mesoblast Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
2 days ago
United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage
Neutral
GlobeNewsWire
6 days ago
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, is now available for purchase in the United States.
Neutral
GlobeNewsWire
19 days ago
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for Ryoncil® is now available in all four major drug pricing compendia in the United States. These pricing compendia provide the official source for all information required to order product, inc...
More Mesoblast Limited Sponsored ADR News

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today